At and for the year ended December 31, 2023

Biopharmaceutical
and Diagnostic
Solutions

Engineering

Total
segments

Adjustments,
eliminations
and
unallocated
items

Consolidated

(EUR thousand)

External customers

879,288

206,066

1,085,354

—

1,085,354

Inter-segment

2,049

166,741

168,790

(168,790

)

—

Total revenue

881,337

372,807

1,254,144

(168,790

)

1,085,354

Cost of sales

591,107

294,550

885,657

(140,196

)

745,461

Gross Profit

290,230

78,257

368,487

(28,594

)

339,893

Other operating income

10,630

16

10,646

(223

)

10,423

Selling and marketing expenses

20,970

3,948

24,918

60

24,978

Research and development expenses

27,653

7,420

35,073

599

35,672

General and administrative expenses

64,658

13,290

77,948

10,998

88,946

Operating Profit

187,579

53,615

241,194

(40,474

)

200,720

of which amortization and depreciation

75,320

3,821

79,141

(661

)

78,480

Total assets

1,614,801

539,598

2,154,399

(82,822

)

2,071,577

Total liabilities

658,954

398,044

1,056,998

(118,067

)

938,931

At and for the year ended December 31, 2022

Biopharmaceutical
and Diagnostic
Solutions

Engineering

Total
segments

Adjustments,
eliminations
and
unallocated
items

Consolidated

(EUR thousand)

External customers

799,652

184,028

983,680

—

983,680

Inter-segment

1,585

115,472

117,057

(117,057

)

—

Total revenue

801,237

299,500

1,100,737

(117,057

)

983,680

Cost of sales

526,370

234,826

761,196

(97,317

)

663,879

Gross Profit

274,867

64,674

339,541

(19,740

)

319,801

Other operating income

18,985

13

18,998

(148

)

18,850

Selling and marketing expenses

12,287

2,430

14,717

11,369

26,086

Research and development expenses

25,169

6,542

31,711

2,676

34,387

General and administrative expenses

73,816

14,431

88,247

(2,500

)

85,747

Operating Profit

182,580

41,284

223,864

(31,433

)

192,431

of which amortization and depreciation

62,401

3,591

65,992

(1,170

)

64,822

Total assets

1,259,124

370,851

1,629,975

29,723

1,659,698

Total liabilities

511,022

256,835

767,857

(104,069

)

663,788

At and for the year ended December 31, 2021

Biopharmaceutical
and Diagnostic
Solutions

Engineering

Total
segments

Adjustments,
eliminations
and
unallocated
items

Consolidated

(EUR thousand)

External customers

694,038

149,882

843,920

—

843,920

Inter-segment

1,134

68,979

70,113

(70,113

)

—

Total revenue

695,172

218,861

914,033

(70,113

)

843,920

Cost of sales

465,304

176,604

641,908

(63,393

)

578,515

Gross Profit

229,868

42,257

272,125

(6,720

)

265,405

Other operating income

9,386

—

9,386

—

9,386

Selling and marketing expenses

7,736

3,196

10,932

9,516

20,448

Research and development expenses

23,467

4,263

27,730

1,886

29,616

General and administrative expenses

58,996

11,898

70,894

(8,392

)

62,502

Operating Profit

149,055

22,900

171,955

(9,730

)

162,225

of which amortization and depreciation

54,487

3,656

58,143

(1,760

)

56,383